VAST, the company behind text-to-3D platform Tripo, raised ~$446M across Series B and B+ — pushing AI 3D generation into foundation-model territory.
Spanish startup iPronics raised a $125M Series B, with Nvidia participating, to swap copper for light and rewire AI data centers in sub-milliseconds.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
Hugging Face's Microduck is a $399 open-source biped that walks, falls, and self-recovers, retrainable with reinforcement learning, while the cheapest humanoid still starts at $13,500.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
Samsung led a EUR3 billion Series D into Mistral AI, nearly doubling the French lab's valuation to about $24 billion in a year - with ASML and Nvidia along for the ride.
🔥 Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Bending Spoons is buying Airtable for $1.285 billion in all cash — about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
BrainChild Bio raised $116M to run the pivotal trial for BCB-276, a CAR-T that pushed DIPG survival from ~11 to 19.8 months in a cancer that has beaten every drug for 50 years.
Eli Lilly is paying up to $2.88 billion for Merida Biosciences, a 16-month-old startup whose lead autoimmune drug is still in Phase 1.
Revolution Medicines' RASONQUE is the first broad RAS-targeted pill for metastatic pancreatic cancer, nearly doubling median survival to 13.2 months. The catch: $39,800 a month.
